Professor Hashim Ahmed’s prostate research, particularly the landmark PROMIS study, transformed prostate cancer diagnosis by demonstrating that multiparametric MRI (mpMRI) should be performed before biopsy in many men with suspected prostate cancer. His work has influenced international clinical practice by improving cancer detection, reducing unnecessary biopsies, and supporting the shift towards safer transperineal biopsy techniques.
On this Page
Professor Hashim Ahmed Prostate Study: Why It Matters
Few researchers have influenced modern prostate cancer diagnosis as profoundly as Professor Hashim Ahmed. Over the past decade, his clinical research has helped reshape how clinicians investigate suspected prostate cancer, replacing older diagnostic pathways with approaches that are both more accurate and significantly safer for patients.
Today, many hospitals across the UK and internationally follow a diagnostic pathway that begins with multiparametric MRI (mpMRI) before biopsy, a practice strongly supported by evidence from the PROMIS (Prostate MR Imaging Study), one of Professor Ahmed’s most influential research projects.
For patients, this means fewer unnecessary biopsies, better detection of clinically significant prostate cancer, and a lower risk of complications.
Who Is Professor Hashim Ahmed?
Professor Hashim U. Ahmed is an internationally recognised urologist and prostate cancer researcher. He serves as Professor of Urology at Imperial College London and leads the Imperial Prostate Research Group, a multidisciplinary team focused on improving the diagnosis and treatment of prostate diseases.
His research has centred on several major areas:
- Earlier detection of clinically significant prostate cancer
- MRI-guided diagnostic pathways
- Transperineal prostate biopsy
- Focal therapy for localised prostate cancer
- Artificial intelligence in prostate imaging
- Population-based prostate cancer screening
Rather than simply finding more prostate cancers, Professor Ahmed’s work aims to identify the cancers that genuinely require treatment while avoiding unnecessary procedures for low-risk disease.
The PROMIS Study Explained
The study most commonly associated with Professor Hashim Ahmed is the PROMIS (Prostate MR Imaging Study).
Published in The Lancet in 2017, PROMIS was designed to answer a question that had challenged urologists for years:
Should MRI be performed before prostate biopsy?
Before PROMIS, many men with elevated PSA levels underwent random transrectal ultrasound-guided (TRUS) biopsies as the first diagnostic step.
This traditional approach had several limitations:
- Some clinically significant cancers were missed.
- Many men underwent unnecessary biopsies.
- TRUS biopsies carried a higher risk of infection because the needle passed through the rectal wall.
- Low-risk cancers that might never cause harm were sometimes overdiagnosed.
Professor Ahmed and his colleagues believed that MRI could improve patient selection before biopsy, but robust evidence was needed.
How the PROMIS Study Was Conducted
PROMIS was a prospective, paired validation study involving 576 men with suspected prostate cancer across multiple UK centres.
Every participant underwent:
- Multiparametric MRI
- Standard TRUS biopsy
- Template mapping biopsy (considered the most accurate reference standard)
Importantly, all three tests were performed independently, allowing researchers to compare their diagnostic performance objectively.
This study design made PROMIS one of the most rigorous investigations ever conducted into prostate cancer diagnosis.
Read: Transrectal Prostate Biopsy
Key Findings from the PROMIS Study
The results fundamentally changed clinical practice.
| Finding | Clinical Impact |
| mpMRI detected approximately 93% of clinically significant prostate cancers | Improved detection of aggressive disease |
| TRUS biopsy detected approximately 48% | Demonstrated limitations of random biopsy |
| MRI-first strategy could reduce unnecessary biopsies | Fewer men undergo invasive procedures |
| Better identification of patients needing targeted biopsy | Improved diagnostic precision |
These findings provided compelling evidence that MRI should be used before biopsy rather than after it.
How Professor Ahmed’s Research Changed Clinical Practice
The impact of Professor Ahmed’s research extends far beyond one clinical trial.
Following PROMIS and subsequent supporting evidence, many healthcare systems adopted an MRI-first diagnostic pathway for men with suspected prostate cancer. This approach is reflected in modern clinical guidance and has become standard practice in many centres.
The benefits include:
- Better detection of clinically significant prostate cancer
- Reduced overdiagnosis of low-risk disease
- Fewer unnecessary biopsies
- Improved patient counselling
- More targeted treatment planning
Instead of performing systematic random biopsies on every patient with an elevated PSA, clinicians can now use MRI findings to decide whether a biopsy is needed and where suspicious lesions should be sampled.
This shift has improved both diagnostic accuracy and patient experience.
The Shift Towards Safer Transperineal Biopsies
Professor Ahmed has also been a leading advocate for the transition from transrectal to transperineal prostate biopsy.
Historically, TRUS biopsies involved passing biopsy needles through the rectal wall, increasing the risk of bacterial infection and, in some cases, sepsis.
Modern transperineal biopsy techniques instead pass the needle through the skin between the scrotum and anus (the perineum), significantly reducing infection risk while allowing better access to difficult-to-reach areas of the prostate.
This evolution complements the MRI-first pathway, enabling clinicians to perform targeted transperineal biopsies directed at lesions identified on MRI rather than relying solely on systematic sampling.
Professor Ahmed’s Research Beyond PROMIS
Although the PROMIS study is Professor Hashim Ahmed’s best-known contribution, it represents only one part of a much broader body of research. Over the past two decades, his work has consistently focused on making prostate cancer diagnosis and treatment more accurate, less invasive, and more personalised.
One of his major areas of interest is focal therapy, an approach that treats only the cancerous portion of the prostate while preserving as much healthy tissue as possible. Traditional treatments such as radical prostatectomy or whole-gland radiotherapy are highly effective but can carry significant risks of urinary incontinence and erectile dysfunction. Professor Ahmed’s research has explored whether carefully selected patients can achieve comparable cancer control with fewer side effects through focal treatments such as High-Intensity Focused Ultrasound (HIFU), cryotherapy, and irreversible electroporation (NanoKnife).
Rather than promoting focal therapy as a replacement for surgery or radiotherapy, Professor Ahmed has consistently advocated for evidence-based patient selection, emphasising that treatment decisions should depend on tumour characteristics, imaging findings, and long-term outcomes. This balanced approach has helped move focal therapy from an experimental concept to an increasingly recognised option for carefully selected men.
Advancing MRI-Guided Precision Medicine
Professor Ahmed’s research has also contributed to the growing use of MRI-guided precision medicine in urology.
Before the widespread adoption of multiparametric MRI (mpMRI), prostate biopsies often involved taking systematic samples throughout the gland without knowing precisely where a tumour was located. Modern MRI allows radiologists to identify suspicious lesions before biopsy, enabling clinicians to target those areas more accurately.
This approach offers several advantages:
- Improved detection of clinically significant prostate cancer
- Reduced diagnosis of clinically insignificant disease
- Fewer repeat biopsy procedures
- Better treatment planning
- Greater confidence for patients considering active surveillance
These principles now underpin prostate cancer diagnostic pathways in many countries and are reflected in international clinical guidance.
Why Professor Hashim Ahmed’s Research Matters Today
Few clinical researchers have influenced prostate cancer diagnosis as comprehensively as Professor Ahmed.
His work has helped shift prostate cancer care from a one-size-fits-all approach towards a pathway centred on precision medicine:
| Before PROMIS | Modern Diagnostic Pathway |
| PSA → Random TRUS biopsy | PSA → mpMRI → Targeted biopsy (if indicated) |
| Higher infection risk | Increasing adoption of transperineal biopsy |
| More unnecessary biopsies | MRI helps avoid biopsy in selected men |
| Random sampling | MRI-targeted sampling |
| Greater overdiagnosis | Better detection of clinically significant cancer |
This evolution has improved diagnostic accuracy while reducing unnecessary procedures for many patients.
Conclusion
Professor Hashim Ahmed’s prostate studies have fundamentally reshaped the way prostate cancer is diagnosed and managed. From the landmark PROMIS trial to ongoing research in focal therapy and AI-assisted imaging, his work has consistently focused on improving patient outcomes through more accurate diagnosis, fewer unnecessary procedures, and personalised treatment pathways.
For patients, these advances mean better-informed decisions and access to safer diagnostic techniques. For clinicians and researchers, Professor Ahmed’s work continues to provide the evidence base for modern prostate cancer care and remains one of the most influential bodies of research in contemporary urology.
FAQs
What is Professor Hashim Ahmed best known for?
Professor Hashim Ahmed is best known for leading research into MRI-based prostate cancer diagnosis, particularly the landmark PROMIS study, which demonstrated that multiparametric MRI should be performed before biopsy in many men with suspected prostate cancer.
What did the PROMIS study prove?
The study showed that multiparametric MRI detected significantly more clinically significant prostate cancers than standard transrectal ultrasound-guided biopsy and could help reduce unnecessary biopsies.
Has Professor Ahmed researched focal therapy?
Yes. Professor Ahmed has published extensively on focal therapy, evaluating technologies such as HIFU, cryotherapy, and NanoKnife while emphasising careful patient selection and the need for robust clinical evidence.
Is MRI before biopsy now standard practice?
In many healthcare systems, yes. MRI-first pathways are now widely recommended because they improve the detection of clinically significant prostate cancer and reduce unnecessary biopsies.
